179 related articles for article (PubMed ID: 30586008)
21. A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis.
Harrison SA; Ruane PJ; Freilich B; Neff G; Patil R; Behling C; Hu C; Shringarpure R; de Temple B; Fong E; Tillman EJ; Rolph T; Cheng A; Yale K
JHEP Rep; 2023 Jan; 5(1):100563. PubMed ID: 36644237
[TBL] [Abstract][Full Text] [Related]
22. Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial.
Joy TR; McKenzie CA; Tirona RG; Summers K; Seney S; Chakrabarti S; Malhotra N; Beaton MD
World J Gastroenterol; 2017 Jan; 23(1):141-150. PubMed ID: 28104990
[TBL] [Abstract][Full Text] [Related]
23. Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis.
Balmer ML; Siegrist K; Zimmermann A; Dufour JF
Liver Int; 2009 Sep; 29(8):1184-8. PubMed ID: 19422479
[TBL] [Abstract][Full Text] [Related]
24. Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial.
Bril F; Portillo Sanchez P; Lomonaco R; Orsak B; Hecht J; Tio F; Cusi K
J Clin Endocrinol Metab; 2017 Aug; 102(8):2950-2961. PubMed ID: 28575232
[TBL] [Abstract][Full Text] [Related]
25. Vitamin E does not prevent Western diet-induced NASH progression and increases metabolic flux dysregulation in mice.
Hasenour CM; Kennedy AJ; Bednarski T; Trenary IA; Eudy BJ; da Silva RP; Boyd KL; Young JD
J Lipid Res; 2020 May; 61(5):707-721. PubMed ID: 32086244
[TBL] [Abstract][Full Text] [Related]
26. Use of metabolic syndrome severity to assess treatment with vitamin E and pioglitazone for non-alcoholic steatohepatitis.
Gurka MJ; Mack JA; Chi X; DeBoer MD
J Gastroenterol Hepatol; 2021 Jan; 36(1):249-256. PubMed ID: 32506513
[TBL] [Abstract][Full Text] [Related]
27. Is it time to screen for the haptoglobin genotype to assess the cardiovascular risk profile and vitamin E therapy responsiveness in patients with diabetes?
Vardi M; Levy AP
Curr Diab Rep; 2012 Jun; 12(3):274-9. PubMed ID: 22427005
[TBL] [Abstract][Full Text] [Related]
28. Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis.
Hoofnagle JH; Van Natta ML; Kleiner DE; Clark JM; Kowdley KV; Loomba R; Neuschwander-Tetri BA; Sanyal AJ; Tonascia J;
Aliment Pharmacol Ther; 2013 Jul; 38(2):134-43. PubMed ID: 23718573
[TBL] [Abstract][Full Text] [Related]
29. Impact of Vitamin E supplementation on vascular function in haptoglobin genotype stratified diabetes patients (EVAS Trial): a randomised controlled trial.
Dalan R; Goh LL; Lim CJ; Seneviratna A; Liew H; Seow CJ; Xia L; Chew DEK; Leow MKS; Boehm BO
Nutr Diabetes; 2020 Apr; 10(1):13. PubMed ID: 32341356
[TBL] [Abstract][Full Text] [Related]
30. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.
Vilar-Gomez E; Martinez-Perez Y; Calzadilla-Bertot L; Torres-Gonzalez A; Gra-Oramas B; Gonzalez-Fabian L; Friedman SL; Diago M; Romero-Gomez M
Gastroenterology; 2015 Aug; 149(2):367-78.e5; quiz e14-5. PubMed ID: 25865049
[TBL] [Abstract][Full Text] [Related]
31. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
Eslami L; Merat S; Malekzadeh R; Nasseri-Moghaddam S; Aramin H
Cochrane Database Syst Rev; 2013 Dec; (12):CD008623. PubMed ID: 24374462
[TBL] [Abstract][Full Text] [Related]
32. Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme.
Cusi K; Sattar N; García-Pérez LE; Pavo I; Yu M; Robertson KE; Karanikas CA; Haupt A
Diabet Med; 2018 Oct; 35(10):1434-1439. PubMed ID: 29869810
[TBL] [Abstract][Full Text] [Related]
33. A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis.
Wah Kheong C; Nik Mustapha NR; Mahadeva S
Clin Gastroenterol Hepatol; 2017 Dec; 15(12):1940-1949.e8. PubMed ID: 28419855
[TBL] [Abstract][Full Text] [Related]
34. Identifying Predictors of Response to Vitamin E for the Treatment of Pediatric Nonalcoholic Steatohepatitis.
Yodoshi T; Orkin S; Arce-Clachar AC; Bramlage K; Su W; Fei L; Xanthakos SA; Mouzaki M
JPEN J Parenter Enteral Nutr; 2020 Sep; 44(7):1301-1307. PubMed ID: 31985850
[TBL] [Abstract][Full Text] [Related]
35. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
[No Abstract] [Full Text] [Related]
36. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis.
Harrison SA; Goodman Z; Jabbar A; Vemulapalli R; Younes ZH; Freilich B; Sheikh MY; Schattenberg JM; Kayali Z; Zivony A; Sheikh A; Garcia-Samaniego J; Satapathy SK; Therapondos G; Mena E; Schuppan D; Robinson J; Chan JL; Hagerty DT; Sanyal AJ
J Hepatol; 2020 May; 72(5):816-827. PubMed ID: 31887369
[TBL] [Abstract][Full Text] [Related]
37. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Sanyal AJ; Chalasani N; Kowdley KV; McCullough A; Diehl AM; Bass NM; Neuschwander-Tetri BA; Lavine JE; Tonascia J; Unalp A; Van Natta M; Clark J; Brunt EM; Kleiner DE; Hoofnagle JH; Robuck PR;
N Engl J Med; 2010 May; 362(18):1675-85. PubMed ID: 20427778
[TBL] [Abstract][Full Text] [Related]
38. Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes.
Bril F; Kalavalapalli S; Clark VC; Lomonaco R; Soldevila-Pico C; Liu IC; Orsak B; Tio F; Cusi K
Clin Gastroenterol Hepatol; 2018 Apr; 16(4):558-566.e2. PubMed ID: 29223443
[TBL] [Abstract][Full Text] [Related]
39. Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2-2 genotype.
Asleh R; Blum S; Kalet-Litman S; Alshiek J; Miller-Lotan R; Asaf R; Rock W; Aviram M; Milman U; Shapira C; Abassi Z; Levy AP
Diabetes; 2008 Oct; 57(10):2794-800. PubMed ID: 18599520
[TBL] [Abstract][Full Text] [Related]
40. Effect of vitamin E supplementation on aminotransferase levels in patients with NAFLD, NASH, and CHC: results from a meta-analysis.
Ji HF; Sun Y; Shen L
Nutrition; 2014 Sep; 30(9):986-91. PubMed ID: 24976430
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
